NDATOPICALGEL
Approved
Aug 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
6/8 — Strong
VALCHLOR (mechlorethamine hydrochloride) by Helsinn is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 2013.
Drug data last refreshed 11m ago · AI intelligence enriched 11m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALCHLOR is a topical gel formulation of mechlorethamine hydrochloride, an alkylating agent approved in 2013 for cutaneous T-cell lymphoma. It works through DNA alkylation, disrupting cancer cell replication at the site of application. This topical delivery enables localized chemotherapy with potentially reduced systemic toxicity.
$13MPart D
LOE Approaching2.7 years to LOELate-stage product with modest Part D spending ($13M, 1,754 claims in 2023) indicates a niche market; commercial teams should expect resource optimization and transition planning.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Started Dec 2023
10 enrolled
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Why This Matters for Your Career
Worked on VALCHLOR at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.